CELLINK
The world’s leading bioconvergence company.
Market cap
$309m
Enterprise value
$407m
Share price
SEK35.88 BICO.ST
Recent deals
- biotechnology
- horizon europe
- sustainable development goals
- dt and ls
- testing
- verified unicorns and $1b exits
- medical testing
- verified thoroughbreds
- 3d printing
- tech for biotech and pharma
- polymers
- biomaterials
- medical research
- post ipo $1b
- modeling
- biomedical
- from $1b exit to zebra
- tissue engineering
- microfluidics
- regenerative medicine
- stem cells
loading funding rounds…
AP4(exited)
Carl Bennet(exited)
Claes Dinkelspiel(exited)
European Innovation Council(exited)
Franklin Templeton Investments(exited)
Eurostars SME programme(exited)
Vinnova(exited)
Band of Angels(exited)
Svenska Handelsbanken(exited)
GU Ventures AB(exited)
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 611 % | 78 % | - | (13 %) | (2 %) | 9 % | 8 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 3 % | 14 % | 15 % | 2 % | 9 % | 10 % | 13 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (18 %) | (37 %) | (88 %) | - | (15 %) | (4 %) | 1 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | 15 % | 18 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by CELLINK
Edit
ACQUISITION by CELLINK Aug 2020
ACQUISITION by CELLINK May 2021
ACQUISITION by CELLINK Aug 2019
ACQUISITION by CELLINK Feb 2021
ACQUISITION by Lab14 Nov 2024
ACQUISITION by Sartorius Apr 2025
ACQUISITION by CELLINK Jun 2021
ACQUISITION by CELLINK May 2022